Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for Prevention of Recurrent Stroke Trial
NCT07174414Phase 3Not yet recruiting
- Sponsor
- Stanford University
- Start
- Oct 2026
- Primary completion
- Jul 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cilostazol in stroke, myocardial infarction (MI), sponsored by Stanford University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cilostazol
03
Conditions
strokemyocardial infarction (MI)
Beyond the preview
Go deeper on NCT07174414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174414.